CN116077560A - Application of EGCG composition in preparation of medicines for treating novel coronaviruses - Google Patents

Application of EGCG composition in preparation of medicines for treating novel coronaviruses Download PDF

Info

Publication number
CN116077560A
CN116077560A CN202310047734.4A CN202310047734A CN116077560A CN 116077560 A CN116077560 A CN 116077560A CN 202310047734 A CN202310047734 A CN 202310047734A CN 116077560 A CN116077560 A CN 116077560A
Authority
CN
China
Prior art keywords
time
vitamin
egcg
use according
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310047734.4A
Other languages
Chinese (zh)
Inventor
赵汉玺
贾丽
朱婉琦
邢力刚
孟祥姣
李晓琳
赵红
尹笑颜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Hospital of Shandong First Medical University
Original Assignee
Cancer Hospital of Shandong First Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Hospital of Shandong First Medical University filed Critical Cancer Hospital of Shandong First Medical University
Priority to CN202310047734.4A priority Critical patent/CN116077560A/en
Publication of CN116077560A publication Critical patent/CN116077560A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention belongs to the technical field of medicines, and particularly relates to application of an EGCG composition in preparation of medicines for treating novel coronaviruses and variant strains. Compared with the single EGCG, the composition has obviously improved therapeutic effect on the novel coronavirus, can improve the blood oxygen saturation of a resting state, improve respiratory symptoms, regulate and control laboratory inflammation indexes and improve lung imaging conditions.

Description

Application of EGCG composition in preparation of medicines for treating novel coronaviruses
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to application of an EGCG composition in preparation of medicines for treating novel coronaviruses and variant strains.
Background
The novel coronavirus (SARS-CoV-2, namely, COVID-19) has the characteristics of strong infectivity and various infection ways, is difficult to prevent and control, has the characteristic of high-speed mutation, has not been able to master the general appearance of the novel coronavirus at present, and is difficult to develop medicines capable of effectively treating. Because of individual differences, the symptoms presented by each individual are different in the face of the infection of the novel coronavirus, the symptoms presented by the patient can be more than tens of types, the respiratory tract symptoms are mainly taken as the main symptoms, and typical symptoms are mainly fever, cough, general weakness, expectoration, shortness of breath and the like, and digestive system symptoms, nervous system symptoms, general symptoms and the like can also appear.
Chinese patent CN 111387194A discloses a compound for preventing and treating new coronavirus infection, the active ingredient is prepared from tea extract, and the main ingredient comprises epigallocatechin gallate EGCG, structural modifier thereof, ECG and GCG analogue.
Disclosure of Invention
The invention overcomes the defects of the prior art, provides a composition comprising EGCG and peach kernel, and also provides application of the composition in preparing medicines for treating novel coronaviruses and variant strains.
Specifically, the technical scheme of the invention is as follows:
the present invention provides a pharmaceutical composition comprising: (1) EGCG, and (2) peach kernel.
A second object of the present invention is to provide the use of the above composition comprising EGCG and peach kernel in the preparation of a medicament for the treatment of novel coronaviruses and variant strains.
The novel coronavirus (SARS-CoV-2) is Beta coronavirus, the novel coronavirus variant strain refers to recombinant strains generated when different subtypes or offspring branches of the novel coronavirus are infected with human bodies simultaneously and are respectively Alpha (Alpha, B.1.1.7), beta (Beta, B.1.351), gamma (Gamma, P.1), delta (Delta, B.1.617.2) and Omicron (Omicron, B.1.1.529) in the process of epidemic and transmission of the novel coronavirus (SARS-CoV-2) in the population. Wherein the 5 subtypes of armin (ba.1, ba.2, ba.3, ba.4, ba.5) have evolved successively into 709 of the series of progeny sub-branches, 72 of which the new armin Rong Ya branch will continue to emerge as new coronaviruses continue to spread worldwide.
Wherein the medicinal dosage of EGCG in the composition is 10mg-1000 mg/day, and the medicinal dosage of EGCG can be any one point value of 10 mg/time, 20 mg/time, 50 mg/time, 75 mg/time, 100 mg/time, 150 mg/time, 200 mg/time, 250 mg/time, 280 mg/time, 300 mg/time, 310 mg/time, 320 mg/time, 325 mg/time, 330 mg/time, 340 mg/time, 350 mg/time, 380 mg/time, 400 mg/time, 500 mg/time, 600 mg/time, 700 mg/time, 800 mg/time, 900 mg/time, 1000 mg/time, and 10mg-1000 mg/day as medicinal dosage. Preferably, the medicinal dosage of EGCG is 325 mg/day.
Wherein, the medicinal dose of the peach kernel in the composition is 10 mg/time to 1000 mg/day, and the medicinal dose of the peach kernel can be any one point value of 10 mg/time, 20 mg/time, 50 mg/time, 70 mg/time, 80 mg/time, 90 mg/time, 95 mg/time, 100 mg/time, 105 mg/time, 110 mg/time, 120 mg/time, 130 mg/time, 140 mg/time, 150 mg/time, 200 mg/time, 300 mg/time, 400 mg/time, 500 mg/time, 600 mg/time, 700 mg/time, 800 mg/time, 900 mg/time, 1000 mg/time and 10mg to 1000 mg/day as the medicinal dose. Preferably, the medicinal dosage of the peach kernel is 100 mg/day.
Further, the pharmaceutical composition provided by the invention can relieve/treat symptoms caused by infection of novel coronaviruses and variant strains, and comprises the following components: one or more of respiratory symptoms, digestive symptoms, nervous system symptoms, fever, weakness, muscle pain, joint pain symptoms, skin symptoms, eye symptoms.
The symptoms include dry throat, sore throat, cough, fever, persistent fever, muscle soreness, hyposmia or loss, nasal obstruction, nasal discharge, vomiting, diarrhea, rash, mucosal inflammation, conjunctivitis, pneumonia, dyspnea, shortness of breath, hoarseness, wheezing, lung wheezing, acute laryngitis, laryngotracheitis, hypoxia, febrile convulsion, encephalitis, meningitis, encephalopathy, acute necrotizing encephalopathy, acute disseminated cerebrospinal meningitis, guillain-Barre syndrome, systemic inflammatory syndrome (MIS-C), hypotension or shock, coagulation disorder acute respiratory distress syndrome, sepsis shock, metabolic acidosis which is difficult to correct, coagulation dysfunction, multiple organ failure, central nervous system involvement, and the like.
Furthermore, the pharmaceutical composition provided by the invention can regulate and control blood oxygen concentration, total white blood cells in peripheral blood, inflammatory factors, myocardial enzymes, liver enzymes, creatinine, lymphocyte levels, liver enzymes, lactate dehydrogenase, myoenzymes, myoglobin, troponin, ferritin, C-reactive protein, blood sedimentation and procalcitonin levels.
Furthermore, the pharmaceutical composition provided by the invention can raise the cycle threshold (Ct value) of nucleic acid detection.
Further, the pharmaceutical composition can be prepared into a preparation with pharmaceutically acceptable auxiliary materials; the preparation is granule, mixture, oral liquid, syrup, tablet, capsule, pill, powder, microcapsule, paste, or inhalant, preferably inhalant.
Further, the inhalation formulation further comprises vitamins.
Wherein, the vitamins participate in the biochemical reaction of the human body, can regulate the metabolic function of the human body, supplement partial nutrition required by the human body, improve the resistance of the human body and be beneficial to the gradual improvement of novel coronavirus infected people.
The vitamins are at least one selected from vitamin B1, vitamin B2, nicotinic acid, vitamin B6, vitamin H, vitamin B5, vitamin C, vitamin A, vitamin D, vitamin E, vitamin K, vitamin B12, and folic acid, preferably vitamin B2 and vitamin C.
Further, the pharmaceutical dosage of the vitamin is 10 mg/time, 20 mg/time, 30 mg/time, 40 mg/time, 50 mg/time, 60 mg/time, 70 mg/time, 80 mg/time, 90 mg/time, 100 mg/time, 110 mg/time, 120 mg/time, 130 mg/time, 140 mg/time, 150 mg/time, 160 mg/time, 170 mg/time, 180 mg/time, 190 mg/time, 200 mg/time, 210 mg/time, 220 mg/time, 230 mg/time, 240 mg/time, 250 mg/time.
Further, the inhalation formulation further comprises an organic acid for the purpose of adding the organic acid: (1) the organic acid can inhibit the growth and reproduction of microorganisms (viruses) to a certain extent. (2) The organic acid has the effect of resisting oxidation free radicals, and can improve the chemical stability of the medicine and the overall stability of the preparation. (3) The organic acid can enhance the immunity and the resistance of human bodies to a certain extent and reduce the invasion of viruses or bacteria. (4) The organic acid can regulate the pH value of the preparation. (5) The organic acid can increase the solubility of the drug in the formulation.
The organic acid is at least one selected from citric acid, malic acid, tartaric acid, acetic acid, succinic acid, oxalic acid and citric acid, preferably citric acid.
Furthermore, the inhalant also contains sodium chloride, and the sodium chloride can participate in the regulation of some acid-base balance in human bodies, maintain the osmotic pressure of extracellular fluid of the bodies, protect cells and play an effective role in nerve conduction.
A third object of the present invention is to provide a method for preparing the inhalation formulation of ECGC composition, comprising:
(1) Cleaning semen Persicae, mashing, and extracting volatile oil by steam distillation;
(2) Collecting the peach kernel dregs obtained in the step (1), adding 4-6 times of water, decocting for 2 times with water for 30-60min each time, mixing decoctions, cooling, adding 2-4 times of ethanol into the decoctions, standing, centrifuging, and collecting supernatant for later use;
(3) Adding the volatile oil, EGCG, vitamins, organic acid and sodium chloride obtained in the step (1) into the supernatant obtained in the step (2), dissolving, filtering, sealing, sterilizing and sub-packaging.
Compared with the prior art, the invention has the beneficial effects that:
compared with EGCG single drug, the composition has the advantages that the therapeutic effect on the novel coronavirus is obviously improved, the oxygen saturation of resting state can be improved, the respiratory symptoms can be improved, the laboratory inflammation index can be regulated, and the lung imaging condition can be improved.
Drawings
Fig. 1-3: imaging change condition of clinical patient
Detailed Description
The present invention will be further described with reference to examples for the purpose of making the objects and technical aspects of the present invention more apparent, but the scope of the present invention is not limited to these examples, which are only for explaining the present invention. It will be understood by those skilled in the art that variations or equivalent substitutions that do not depart from the spirit of the invention are intended to be included within the scope of the invention.
EXAMPLE 1EGCG composition inhalation formulation
(1) Cleaning semen Persicae, removing impurities, mashing, and extracting volatile oil by steam distillation;
(2) Collecting the peach kernel dregs obtained in the step (1), adding 4-6 times of water, decocting for 2 times with water for 30-60min each time, mixing decoctions, cooling, adding 2-4 times of ethanol into the decoctions, standing, centrifuging, and collecting supernatant for later use;
(3) Adding the volatile oil, EGCG, vitamins, organic acid and sodium chloride obtained in the step (1) into the supernatant obtained in the step (2), dissolving, filtering, sealing, sterilizing and sub-packaging.
According to clinical medication characteristics, quantitative aerosols can be selected, and the content of each main drug is EGCG10 mg/time, 20 mg/time, 50 mg/time, 75 mg/time, 100 mg/time, 150 mg/time, 200 mg/time, 250 mg/time, 280 mg/time, 300 mg/time, 310 mg/time, 320 mg/time, 325 mg/time, 330 mg/time, 340 mg/time, 350 mg/time, 380 mg/time, 400 mg/time, 500 mg/time, 600 mg/time, 700 mg/time, 800 mg/time, 900 mg/time and 1000 mg/time; 10 mg/time, 20 mg/time, 50 mg/time, 70 mg/time, 80 mg/time, 90 mg/time, 95 mg/time, 100 mg/time, 105 mg/time, 110 mg/time, 120 mg/time, 130 mg/time, 140 mg/time, 150 mg/time, 200 mg/time, 300 mg/time, 400 mg/time, 500 mg/time, 600 mg/time, 700 mg/time, 800 mg/time, 900 mg/time, 1000 mg/time of peach seed.
The content of each pressing seed is 10 mg/time, 20 mg/time, 50 mg/time, 70 mg/time, 80 mg/time, 90 mg/time, 95 mg/time, 100 mg/time, 105 mg/time, 110 mg/time, 120 mg/time, 130 mg/time, 140 mg/time, 150 mg/time, 200 mg/time, 300 mg/time, 400 mg/time, 500 mg/time, 600 mg/time, 700 mg/time, 800 mg/time, 900 mg/time, 1000 mg/time.
Each press contains vitamins in an amount of 10 mg/time, 20 mg/time, 30 mg/time, 40 mg/time, 50 mg/time, 60 mg/time, 70 mg/time, 80 mg/time, 90 mg/time, 100 mg/time, 110 mg/time, 120 mg/time, 130 mg/time, 140 mg/time, 150 mg/time, 160 mg/time, 170 mg/time, 180 mg/time, 190 mg/time, 200 mg/time, 210 mg/time, 220 mg/time, 230 mg/time, 240 mg/time, 250 mg/time.
The preferred embodiment of the invention is that the content of main medicine of each press is EGCG100 mg/time, the content of peach kernel is 50 mg/time, and the content of vitamin is 50 mg/time.
Example 2EGCG composition tablets
(1) Cleaning semen Persicae, removing impurities, mashing, and extracting volatile oil by steam distillation;
(2) Collecting the peach kernel dregs obtained in the step (1), adding 4-6 times of water, decocting for 2 times with water for 30-60min each time, mixing decoctions, cooling, adding 2-4 times of ethanol into the decoctions, standing, centrifuging, and collecting supernatant for later use;
(3) Adding the volatile oil, EGCG, vitamins, organic acid, sodium chloride and auxiliary materials required by the oral liquid in the step (1) into the supernatant obtained in the step (2), and preparing the oral liquid by a conventional method.
Example 3EGCG composition granules
(1) Cleaning semen Persicae, removing impurities, mashing, and extracting volatile oil by steam distillation;
(2) Collecting the peach kernel dregs in the step (1), adding 4-6 times of water, decocting for 2 times with water for 30-60min each time, mixing decoctions, cooling, adding 2-4 times of ethanol into the decoctions, standing, centrifuging, collecting supernatant, heating and concentrating to relative density of 1.05-1.25 to obtain concentrated extract;
(3) Adding the volatile oil, EGCG, vitamins, organic acid, sodium chloride, filler, disintegrating agent and lubricant in the step (1) into the concentrated extract obtained in the step (2), and making into granule by conventional method.
Example 4EGCG composition oral liquid
(1) Cleaning semen Persicae, removing impurities, mashing, and extracting volatile oil by steam distillation;
(2) Collecting the peach kernel dregs in the step (1), adding 4-6 times of water, decocting for 2 times with water for 30-60min each time, mixing decoctions, cooling, adding 2-4 times of ethanol into the decoctions, standing, centrifuging, collecting supernatant, heating and concentrating to relative density of 1.05-1.25 to obtain concentrated extract;
(3) Adding the volatile oil, EGCG, vitamins, organic acid, sodium chloride, filler, disintegrating agent and lubricant in the step (1) into the concentrated extract obtained in the step (2), and making into tablet by conventional method.
Comparative example 1EGCG inhalation formulation
Dissolving EGCG, vitamins, organic acid and sodium chloride in anhydrous ethanol and water, filtering, sealing, sterilizing, and packaging. The dosage is referred to in example 1.
The preferred embodiment of the invention is that the content of main medicine of each press is EGCG100 mg/time and the content of vitamin is 50 mg/time.
Comparative example 2 peach seed inhalation formulation
(1) Cleaning semen Persicae, removing impurities, mashing, and extracting volatile oil by steam distillation;
(2) Collecting the peach kernel dregs obtained in the step (1), adding 4-6 times of water, decocting for 2 times with water for 30-60min each time, mixing decoctions, cooling, adding 2-4 times of ethanol into the decoctions, standing, centrifuging, and collecting supernatant for later use;
(3) Adding the volatile oil, vitamins, organic acid and sodium chloride obtained in the step (1) into the supernatant obtained in the step (2), dissolving, filtering, sealing, sterilizing and sub-packaging. The dosage is referred to in example 1.
The preferred embodiment of the invention is that the content of the main medicine of each press is 50 mg/time of peach seed and the content of vitamin is 50 mg/time.
Comparative example 3EGCG composition inhalation formulation
(1) Cleaning Saviae Miltiorrhizae radix, removing impurities, slicing, and extracting volatile oil by steam distillation;
(2) Collecting the red sage root residue in the step (1), adding 4-6 times of water, decocting for 2 times with water for 30-60min each time, mixing decoctions, cooling, adding 2-4 times of ethanol into the decoctions, standing, centrifuging, and collecting supernatant;
(3) Adding the volatile oil, EGCG, vitamins, organic acid and sodium chloride obtained in the step (1) into the supernatant obtained in the step (2), dissolving, filtering, sealing, sterilizing and sub-packaging. The dosage is referred to in example 1.
The preferred embodiment of the invention is that the content of main medicine of each press is EGCG100 mg/time, the content of red sage root is 50 mg/time, and the content of vitamin is 50 mg/time.
Clinical case analysis of novel coronavirus and variant strain infection treatment effect by using pharmaceutical composition of the invention
1. Reference diagnostic criteria
Reference is made to Beijing co-ordinated hospital breathing and new coronavirus infection diagnosis and treatment protocol of critical medical department and new coronavirus infection diagnosis and treatment protocol (tenth edition of trial).
Diagnosis of New coronavirus infection is classified into New coronavirus infection (epidemiological history+clinical symptoms+nucleic acid/antigen), pneumonia (New coronavirus infection+New imaging abnormality of the lung in accordance with New coronavirus infection)
Classification of new coronavirus infections comprehensively considers oxygenation and dyspnea conditions, severe risk factors (immunosuppression, basic diseases, advanced age), and the extensive degree and progress rate of pneumonia are classified into light, medium, heavy and critical.
2. Clinical case data statistics
The new crown cases 123 were collected from 12 months 2022 to 01 months 2023, and 100 medium-sized new crown patients were screened for age 35-59 years, with average (48.71 + -6.46) years.
2.1 grouping
100 patients were randomly divided into treatment group, control 1 group, control 2 group, control 3 group, 25 groups each, and there were no significant differences in age, sex, and health status between each group prior to treatment.
2.2 medicaments
Treatment group: EGCG composition of example 1 inhaled formulation, dose: 200 mg/day of EGCG, 100 mg/day of peach kernel, 100 mg/time of EGCG and 50 mg/time of peach kernel are contained in each pressing main medicine, and 3 days are continuously carried out each time in the morning and evening.
Control group 1: EGCG inhaled formulation, dosage of comparative example 1: EGCG content is 200 mg/day, and each time main drug content is 100 mg/time EGCG, each time in the morning and evening, 3 days continuously.
Control group 2: peach kernel inhalation formulation, dosage of comparative example 2: 100 mg/day of peach seed, 50 mg/time of peach seed, once in the morning and evening respectively, for 3 consecutive days. .
Control 3 group: the EGCG composition of comparative example 3 was inhaled into formulation, dose: 200 mg/day of EGCG and 100 mg/day of red sage root, wherein the content of main medicine is 100 mg/time of EGCG and 50 mg/time of red sage root, each time in the morning and evening, and 3 days are continuous.
2.3 detection projects and statistics
In order to highlight the treatment effect before and after the administration of the drug and the treatment effect of the drug on patients of different grades, the new patients are counted and compared.
2.3.1 resting State blood oxygen saturation
Blood oxygen saturation is an important physiological parameter reflecting respiratory and circulatory functions, and is an index for measuring the respiratory system functions and the oxygen carrying capacity of blood of a human body. In general, normal adults breathe air in a resting state with a blood oxygen saturation value of 95% -98%, with blood oxygen saturation below 94% indicating a degree of hypoxia, 90-95% being slightly unsaturated, 85-89% indicating moderately unsaturated, and less than 85% indicating severely unsaturated.
TABLE 1 blood oxygen saturation in resting state of patients before and after administration
Figure SMS_1
/>
Figure SMS_2
The clinical data statistics of the table 1 show that the average blood oxygen saturation of the rest state of the patients infected by the medium-sized new coronavirus is about 94%, and after 3 days of treatment, the blood oxygen saturation of the patients in the treatment group is recovered to about 98%, so that the effect is remarkable; the EGCG-peach kernel inhalation preparation prepared in the embodiment 1 of the invention can improve the condition of low blood oxygen saturation caused by novel coronavirus infection, and improve the respiratory and circulatory functions and the oxygen carrying capacity of blood.
2.3.2 total number of white blood cells and total number of lymphocytes in peripheral blood
The total number of white blood cells in the peripheral blood of normal adults is (4-10). Times.10-9/L, and mainly comprises the following five types of neutrophils, lymphocytes, basophils, eosinophils and monocytes. The total number of white blood cells is higher than the upper limit of the normal value (i.e., 10X 10-9/L), and is lower than the lower limit of the normal value (4X 10-9/L), it is called leukopenia. The normal value of lymphocyte number is 20-40% of total leukocyte number, the absolute value is (0.8-4) ×10ζ9, in a certain range, if the increase of lymphocyte number is possible due to in vivo infection, viral infection and bacterial infection are common, the increase of lymphocyte number is caused.
TABLE 2 total number of leukocytes in peripheral blood of mesoscopic patients before and after administration
Figure SMS_3
Figure SMS_4
TABLE 3 total lymphocyte count in mesoscopic patients before and after administration
Figure SMS_5
Lymphocyte total number (10≡9/L)
Treatment group 0.42±0.045 1.49±0.026
Control group 1 0.44±0.023 0.78±0.067
Control group 2 0.38±0.036 0.43±0.033
Control group 3 0.48±0.025 0.86±0.077
Table 2-3 clinical data statistics show that the EGCG-peach kernel inhalation formulation prepared in example 1 of the present invention can improve the increase of total white blood cells in peripheral blood of mesoscopic patients due to novel coronavirus infection, and the total number of lymphocytes in the initial stage of novel coronapatients is 0.2-0.5X10 as far as the total number of lymphocytes is concerned 9 Is reduced from normal, but the total number of lymphocytes increases with treatment. Although an increase in lymphocyte count is generally recognized medically as potentially being infected or as being enhanced by the virus, in the observed patient, an appropriate increase in lymphocyte count contributes to the patient's disease state as regards the specificity of the new coronavirus. Especially in the final inspectionIn the test, the number of lymphocytes in the patient test using EGCG-peach kernel inhalation formulation is 1.1-1.4X10 9 In the range of (2), the respiratory symptoms are significantly improved, and no white lung phenomenon occurs, and the patient is basically healed as a whole.
2.3.3 inflammatory factors-Interleukin 6 (IL-6), hypersensitivity C-reactive protein (CRP), ferritin levels
The level of interleukin 6 (IL-6) in the serum of a patient is detected by ELISA (enzyme-linked immunosorbent assay), the normal range is 0-7ng/L, and the increase of interleukin 6 is a disease which means that the human body resists invasion.
TABLE 4 IL-6 levels in mesoscopic patients before and after administration
Figure SMS_6
Figure SMS_7
CRP (hypersensitive C response protein) is a nonspecific inflammatory marker, and is an acute phase response protein synthesized by liver for protecting body when pathogenic microorganisms invade the body, and the normal level is 0.068-8.2 mg/L.
TABLE 5 CRP levels in mesoscopic patients before and after administration
Figure SMS_8
Figure SMS_9
Ferritin is not only a tumor marker, but also an inflammation index, ferritin in a normal human body can fluctuate within a certain range, and abnormal conditions can only occur when the human body suffers from related diseases.
TABLE 6 ferritin levels in mesoscopic patients before and after administration
Figure SMS_10
Figure SMS_11
Tables 4-6 statistics of clinical data show that EGCG-peach kernel inhalation preparation prepared in example 1 of the invention can regulate and control inflammatory factor indexes, and reduce the rise of interleukin 6 (IL-6) and hypersensitive C Response Protein (CRP) caused by novel coronavirus infection. Because the patient suffers from cancer diseases, the ferritin index is in a higher level, the ferritin content is increased when the patient is infected with novel coronavirus, and the ferritin content in the patient is obviously reduced after 3 days of treatment of the EGCG-peach kernel inhalation preparation of the example 1.
2.3.4 nucleic acid detection Ct value
Cycle threshold (Ct) refers to the number of cycles required to amplify viral RNA to detectable levels at the time of RT-PCR detection. Thus, a lower Ct value may indicate a higher viral level, indicating a relative level of viral RNA in the sample. The Ct value has a reference value of 35, negative above 35 and positive below 35.
TABLE 7 Ct values in patients with intermediate size before and after administration
Figure SMS_12
Figure SMS_13
Figure SMS_14
TABLE 8 days required for middle-sized patients to turn negative before and after administration
Figure SMS_15
Figure SMS_16
Tables 7-8 are statistics of the conversion of patients in the middle-sized group, showing that the number of days the patients converted to the negative was shortened when the treatment was performed according to the treatment regimen.
2.3.5 chest imaging showing pulmonary lesions
FIG. 1 shows a comparison of a patient's four seasons lung imaging, a lung cancer history, 2023, 1 and 4 day lung imaging showing double lung inflammation, 2023, 1 and 9 day review, and a significant improvement in combination with clinical and various indices, compared with the former tablets, with a reduction in double pneumonia.
Figure 2 is a front-to-back comparison of Li Mou lung images of a patient, a history of esophageal cancer, and an esophageal cancer procedure has been performed. The 2023 day 1 month 3 lung image showed multiple spotted sheets, plain strips and nodular density increasing stoves visible in the double lung, with blurred edges, and with the lower lobes of the double lung as the origin, and the part was ground to glass density. Review of the lung images on day 1 and 10 shows a reduction in the double pneumonia, combined with clinical improvement.
FIG. 3 shows a patient with a history of She Feiai on the right lung, showing lung inflammation in 2023, 1 and 11 days of lung imaging, comparing the front and back of a certain lung image; the double lung inflammation is slightly reduced in comparison with the former range, the focus density is partially reduced, and the improvement is considered, so that the follow-up examination after treatment is suggested.
2.4 clinical comprehensive efficacy statistics
Treatment group: 25 patients in the group were all of medium-sized patients.
Control group 1: 25 patients in the group were medium patients.
Control group 3: 25 patients in the group were medium patients.
Control group 2 was not counted because of poor efficacy.
The curative effect evaluation method comprises the following steps: oxygen saturation in resting state before and after administration, respiratory tract symptoms improvement, laboratory inflammation index change before and after administration, and imaging change.
The preliminary results are as follows:
treatment group: the effective rate is 84% (21/25), 1 patient cannot tolerate the disease, and 3 patients have serious symptoms after taking the medicine for 1 time and do not continue taking the medicine.
Control group 1: the effective rate is 52% (13/25), 3 patients cannot tolerate the medicine, and 8 patients have serious symptoms after taking the medicine for 1 time and do not continue to take the medicine.
Control group 3: the effective rate is 48% (12/25), 3 patients cannot tolerate the medicine, and 9 patients have symptoms aggravated after 1 time of administration and do not continue administration.

Claims (10)

1. Use of a pharmaceutical composition for the preparation of a medicament for the treatment of novel coronaviruses and variant strains, said composition comprising: (1) EGCG, and (2) peach kernel.
2. The use according to claim 1, wherein the pharmaceutical dosage of EGCG is 10mg-1000 mg/day, preferably the pharmaceutical dosage of EGCG is 200 mg/day.
3. The use according to claim 1, wherein the pharmaceutical dosage of said peach kernel is 10mg-1000 mg/day, preferably the pharmaceutical dosage of said peach kernel is 100 mg/day.
4. The use according to claim 1, wherein the pharmaceutical composition is capable of alleviating/treating one or more of respiratory symptoms, digestive symptoms, nervous system symptoms, fever, weakness, muscle pain, joint pain, skin symptoms, eye symptoms caused by infection with novel coronaviruses and variant strains.
5. The use according to claim 1, wherein the pharmaceutical composition is capable of modulating blood oxygen concentration, total number of leukocytes in peripheral blood, inflammatory factor, cardiomyopathy, liver enzyme, creatinine, lymphocyte level, liver enzyme, lactate dehydrogenase, myonase, myoglobin, troponin, ferritin, C-reactive protein, blood sedimentation, procalcitonin level.
6. The use according to claim 1, wherein the pharmaceutical composition is formulated with pharmaceutically acceptable excipients; the preparation is granule, mixture, oral liquid, syrup, tablet, capsule, pill, powder, microcapsule, paste, or inhalant, preferably inhalant.
7. The use according to claim 6, wherein the inhalable formulation further comprises vitamins, organic acids, sodium chloride.
8. Use according to claim 7, characterized in that the vitamin is selected from at least one of vitamin B1, vitamin B2, niacin, vitamin B6, vitamin H, vitamin B5, vitamin C, vitamin a, vitamin D, vitamin E, vitamin K, vitamin B12, folic acid, preferably vitamin B2, vitamin C.
9. Use according to claim 7, characterized in that the organic acid is selected from at least one of citric acid, malic acid, tartaric acid, acetic acid, succinic acid, oxalic acid, citric acid, preferably citric acid.
10. The use according to claim 7, wherein the inhalation formulation is prepared by the process of:
(1) Mashing semen Persicae, and extracting volatile oil by steam distillation;
(2) Collecting the peach kernel dregs obtained in the step (1), adding 4-6 times of water, decocting for 2 times with water for 30-60min each time, mixing decoctions, cooling, adding 2-4 times of ethanol into the decoctions, standing, centrifuging, and collecting supernatant for later use;
(3) Adding the volatile oil, EGCG, vitamins, organic acid and sodium chloride obtained in the step (1) into the supernatant obtained in the step (2), dissolving, filtering, sealing, sterilizing and sub-packaging.
CN202310047734.4A 2023-01-31 2023-01-31 Application of EGCG composition in preparation of medicines for treating novel coronaviruses Pending CN116077560A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310047734.4A CN116077560A (en) 2023-01-31 2023-01-31 Application of EGCG composition in preparation of medicines for treating novel coronaviruses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310047734.4A CN116077560A (en) 2023-01-31 2023-01-31 Application of EGCG composition in preparation of medicines for treating novel coronaviruses

Publications (1)

Publication Number Publication Date
CN116077560A true CN116077560A (en) 2023-05-09

Family

ID=86205914

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310047734.4A Pending CN116077560A (en) 2023-01-31 2023-01-31 Application of EGCG composition in preparation of medicines for treating novel coronaviruses

Country Status (1)

Country Link
CN (1) CN116077560A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111387194A (en) * 2020-02-24 2020-07-10 云南农业大学 Compound for efficiently and specifically preventing and treating novel coronavirus infection and application thereof
CN111658631A (en) * 2020-06-11 2020-09-15 广东盛普生命科技有限公司 Application of gallic acid and its derivatives and structural analogs in preparing anti-coronavirus medicine
CN113332363A (en) * 2020-03-02 2021-09-03 中国科学院上海药物研究所 Application of tea extract and composition thereof in resisting coronavirus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111387194A (en) * 2020-02-24 2020-07-10 云南农业大学 Compound for efficiently and specifically preventing and treating novel coronavirus infection and application thereof
CN113332363A (en) * 2020-03-02 2021-09-03 中国科学院上海药物研究所 Application of tea extract and composition thereof in resisting coronavirus
CN111658631A (en) * 2020-06-11 2020-09-15 广东盛普生命科技有限公司 Application of gallic acid and its derivatives and structural analogs in preparing anti-coronavirus medicine
CN112546041A (en) * 2020-06-11 2021-03-26 广东盛普生命科技有限公司 Application of (-) -epigallocatechin gallate in preparing anti-coronavirus medicine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
张依倩;史嘉雯;刘园华;周浩;蔡晓庆;温晋;刘元雪;任红微;王玉;宋兆辉;何毅;孙鹤;周水平;陈韵岱;: "补气活血中药在新型冠状病毒肺炎低氧血症的潜在临床应用价值及其机制浅析", 中草药, vol. 51, no. 06, pages 1435 *
臧青民;章烨雯;: "茶叶中表没食子儿茶素没食子酸酯的研究进展", 福建茶叶, no. 09, pages 1 - 2 *

Similar Documents

Publication Publication Date Title
JP6305407B2 (en) Chinese medicine composition for regulating immunity and method for producing the same
WO2021155777A1 (en) Use of pharmaceutical composition for preventing and treating novel coronavirus pneumonia
CN111110824B (en) Medicinal composition for strengthening body resistance and rescuing lung and application thereof
CN100546620C (en) A kind of Chinese medicine for the treatment of respiratory tract disease and preparation method thereof
CN111214550A (en) New application of medicine in treating or preventing novel coronavirus pneumonia 2019-nCoV
CN117137998B (en) Pharmaceutical composition for treating yin deficiency damp-heat type viral infection and pulmonary nodule, preparation and application thereof
WO2022199049A1 (en) Use of ulinastatin in preparation of drug for treating novel coronavirus pneumonia
CN111329982B (en) Novel application of bupleurum tenue granules in combination with chloroquine phosphate
CN116077560A (en) Application of EGCG composition in preparation of medicines for treating novel coronaviruses
CN115969928A (en) Traditional Chinese medicine composition for treating chronic heart failure and application thereof
WO2021249286A1 (en) New drug formula for immunotherapy and tablet structure thereof
WO2021217702A1 (en) Medicine and food for preventing or treating covid-19, and application thereof
CN106581520B (en) Traditional Chinese medicine granule for treating diffuse interstitial pulmonary fibrosis lung qi deficiency syndrome
CN101530405A (en) Citric acid and compound citric acid application in pharmacy
CN101559114A (en) Application of traditional Chinese medicine composition in preparing antihypoxic
CN112076247A (en) Application of perilla leaf extract in preparation of medicine for treating chronic obstructive pulmonary disease
CN114159474B (en) Application of liushen pills in preparation of medicines for treating fungal pneumonia
CN106309902B (en) Traditional Chinese medicine granule for treating diffuse interstitial pulmonary fibrosis yin deficiency and internal heat syndrome
WO2024114725A1 (en) Formula for tonifying qi, activating blood and detoxificating and use thereof
WO2021213504A1 (en) Use of vegf inhibitor in preparation of medicament for treating hypoxia-related diseases
CN114159533B (en) Traditional Chinese medicine composition for treating multiple drug-resistant bacterial infection and application thereof
CN113440574B (en) Application of traditional Chinese medicine composition in preparation of medicine for treating viral myocarditis
CN107349303B (en) Traditional Chinese medicine composition for treating chronic chest pain and application thereof
CN109394776B (en) Traditional Chinese medicine component formula for treating diffuse interstitial pulmonary fibrosis and application thereof
CN115814030A (en) Traditional Chinese medicine composition for preventing and treating new coronavirus and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination